The Principal Investigator, Kun-Pin Hsieh, PhD, PharmD, is an Associate Professor in the School of Pharmacy at Kaohsiung Medical University (KMU) and a jointly appointed clinical pharmacist at Kaohsiung Medical University Hospital. She received her PharmD in the United States and her PhD in Pharmacy in Taiwan, with prior clinical pharmacy experience in both countries, providing a solid foundation for internationally oriented clinical and research training.

Dr. Hsieh has extensive experience in research-focused talent cultivation, mentoring graduate students and junior researchers in pharmacoepidemiology, medication safety, and outcomes research using large-scale real-world data. Her mentoring emphasizes rigorous study design, data governance, statistical analysis, and academic writing, enabling trainees to develop independent research capability and contribute to peer-reviewed international publications.

In recent years, she has led interdisciplinary projects integrating artificial intelligence, eye-tracking, and digital health technologies into clinical research and pharmacy education, providing IIPP trainees with a structured, research-intensive training environment aligned with NSTC IIPP objectives.

The laboratory focuses on pharmacoepidemiology, medication safety, and outcomes research, integrating real-world data with advanced analytical methods. Core research areas include drug safety evaluation in chronic diseases and cancer pharmacotherapy, cardiovascular and neuropharmacology outcomes, and the assessment of potentially inappropriate medications.

The lab routinely utilizes large-scale healthcare databases and hospital clinical data to conduct population-based and comparative effectiveness studies. In recent years, the research scope has expanded to incorporate artificial intelligence, eye-tracking, and digital health technologies to investigate clinical decision-making processes, prescription review competency, and translational applications in pharmacy education.

Overall, the laboratory aims to generate evidence to inform safer pharmacotherapy, support clinical decision-making, and advance data-driven training for healthcare professionals.